据阿斯利康(AstraZeneca)官网消息,2024年4月5日,一款重磅抗癌药-Enhertu®(DS-8201)获美国食品和药品监督局(FDA)批准,用于治疗既往接受过治疗的转移性HER2阳性实体瘤患者,作为首款获批的针对HER2阳性的泛实体瘤ADC药物,消息一出立...
1. Cortés J, et al. Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine(T-DM1) in Patients With HER2+ Metastatic Breast Cancer: Results of the Randomized. Phase 3 Study DESTINY-Breast03. 2021ESMO, LBA1. 2. Hurviz SA, et al. T...
备受瞩目的ADC神药德曲妥珠单抗（T-DXd，也称为DS-8201）以3480元/支进入医保，新版医保已经在2025年1月1日正式执行!符合以下条件的乳腺癌患者使用DS-8201就能用医保报销了[1]！1.既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。2.既往在转移性疾病阶段接受过至少一种系统治...
7月12日,DS-8201(英文商品名:Enhertu® ,中文商品名:优赫得®,通用名:注射用德曲妥珠单抗/DS-8201)被获批用于治疗既往在转移性疾病阶段接受过至少一种系统治疗的,或在辅助化疗期间或完成辅助化疗之后6个月内复发的,不可切除或转移性HER2低表达(IHC 1 或IHC 2 /ISH-)成人乳腺癌患者。 这是继2023年2月...
4.Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial - PMC (nih.gov)5.Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a ...
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017 Nov;18(11):1512-1522. 3. Tarantino P...
[12] TAMURA K, TSURUTANI J, TAKAHASHI S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study [J]. Lancet Oncology, 2019, ...
4.Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial - PMC (nih.gov) 5.Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a...
3. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).2022 ASCO GI. ...
Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study 2 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung can...